TR201802791T4 - Aril ve heteroaril füzyonlu laktamlar. - Google Patents

Aril ve heteroaril füzyonlu laktamlar. Download PDF

Info

Publication number
TR201802791T4
TR201802791T4 TR2018/02791T TR201802791T TR201802791T4 TR 201802791 T4 TR201802791 T4 TR 201802791T4 TR 2018/02791 T TR2018/02791 T TR 2018/02791T TR 201802791 T TR201802791 T TR 201802791T TR 201802791 T4 TR201802791 T4 TR 201802791T4
Authority
TR
Turkey
Prior art keywords
aryl
heteroaryl fused
fused lactams
salts
compounds
Prior art date
Application number
TR2018/02791T
Other languages
English (en)
Inventor
Paul Edwards Martin
Arnold Kumpf Robert
Kung Pei-Pei
James Mcalpin Indrawan
Ninkovic Sacha
Yuanjin Rui Eugene
Channing Sutton Scott
Howard Tatlock John
James Wythes Martin
Raymond Zehnder Luke
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TR201802791T4 publication Critical patent/TR201802791T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Bu buluş, R1, R2, U, V, L, M, R5, m, X, Y ve Z'nin burada tanımlandığı gibi olduğu genel Formül (I)'e ait bileşikler ve bunların farmasötik açıdan kabul edilebilir tuzları ile, bu bileşikleri ve tuzları içeren farmasötik kompozisyonlar ile ve bu bileşiklerin, tuzların ve kompozisyonların, kanser dahil anormal hücre büyümesi tedavisi için kullanılması yöntemleri ile ilgilidir.
TR2018/02791T 2012-12-21 2013-12-05 Aril ve heteroaril füzyonlu laktamlar. TR201802791T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261740596P 2012-12-21 2012-12-21

Publications (1)

Publication Number Publication Date
TR201802791T4 true TR201802791T4 (tr) 2018-03-21

Family

ID=49917684

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/02791T TR201802791T4 (tr) 2012-12-21 2013-12-05 Aril ve heteroaril füzyonlu laktamlar.

Country Status (46)

Country Link
US (3) US9040515B2 (tr)
EP (2) EP2935238B1 (tr)
JP (1) JP5909308B2 (tr)
KR (1) KR101712441B1 (tr)
CN (1) CN104870435B (tr)
AP (1) AP2015008574A0 (tr)
AR (1) AR094174A1 (tr)
AU (1) AU2013365908C1 (tr)
CA (1) CA2893339C (tr)
CL (1) CL2015001733A1 (tr)
CR (2) CR20200273A (tr)
CU (1) CU24414B1 (tr)
CY (2) CY1119883T1 (tr)
DK (2) DK2935238T3 (tr)
DO (1) DOP2015000157A (tr)
EA (1) EA028317B1 (tr)
EC (1) ECSP15031579A (tr)
ES (2) ES2808987T3 (tr)
GE (1) GEP201706718B (tr)
GT (1) GT201500190A (tr)
HK (1) HK1208866A1 (tr)
HR (2) HRP20180060T1 (tr)
HU (2) HUE050009T2 (tr)
IL (1) IL239520B (tr)
LT (2) LT3339303T (tr)
MA (1) MA38175B1 (tr)
MD (1) MD4664C9 (tr)
ME (2) ME03793B (tr)
MX (2) MX2015008058A (tr)
MY (2) MY176307A (tr)
NO (1) NO2961649T3 (tr)
NZ (1) NZ708801A (tr)
PE (1) PE20151090A1 (tr)
PH (1) PH12015501367A1 (tr)
PL (2) PL2935238T3 (tr)
PT (2) PT2935238T (tr)
RS (2) RS56815B1 (tr)
SG (1) SG11201504076XA (tr)
SI (2) SI2935238T1 (tr)
TN (1) TN2015000281A1 (tr)
TR (1) TR201802791T4 (tr)
TW (1) TWI546293B (tr)
UA (1) UA111305C2 (tr)
UY (2) UY38712A (tr)
WO (1) WO2014097041A1 (tr)
ZA (1) ZA201504437B (tr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2780013A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
AU2013216721B2 (en) 2012-02-10 2017-09-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
GEP201706757B (en) 2012-12-21 2017-10-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2014151142A1 (en) 2013-03-15 2014-09-25 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
MY185765A (en) 2014-06-17 2021-06-06 Pfizer Substituted dihydroisoquinolinone compounds
WO2015193768A1 (en) * 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
JP6571180B2 (ja) * 2014-10-28 2019-09-04 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｚｅｓｔｅホモログ２エンハンサー阻害剤
AR102767A1 (es) 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
US20180271857A1 (en) 2014-12-23 2018-09-27 University Of Copenhagen Treatment of cancer by inhibiting ezh2 activity
AU2016239625B2 (en) * 2015-03-27 2019-10-03 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
TW201708210A (zh) * 2015-06-30 2017-03-01 葛蘭素史克智慧財產（第二）有限公司 Ｚｅｓｔｅ同源物２增強子之抑制劑
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
AU2016357900B2 (en) 2015-11-19 2020-09-17 Jiangsu Hengrui Medicine Co., Ltd. Benzofuran derivative, preparation method thereof and use thereof in medicine
AU2017260854B2 (en) 2016-05-05 2020-01-30 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of Zeste Homolog 2 inhibitors
CN109843870A (zh) 2016-10-19 2019-06-04 星座制药公司 Ezh2抑制剂的合成
CN108699002B (zh) * 2016-11-11 2021-11-09 上海海雁医药科技有限公司 1,5,7-三取代的异喹啉衍生物、其制法与医药上的用途
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
MY198008A (en) 2017-05-18 2023-07-25 Jiangsu Hengrui Medicine Co Crystal of benzofuran derivative free base and preparation method
MX2019012938A (es) 2017-05-18 2019-12-16 Jiangsu Hengrui Medicine Co Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.
CN106977483A (zh) * 2017-06-02 2017-07-25 遵义医学院 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法
BR112020008325A2 (pt) 2017-11-14 2020-10-20 Pfizer Inc. terapias de combinação com o inibidor de ezh2
KR102451529B1 (ko) 2018-01-31 2022-10-06 미라티 테라퓨틱스, 인크. Prc2 억제제
JP2021531340A (ja) 2018-07-09 2021-11-18 フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles 眼障害を治療するためのｐｒｃ２サブユニットの阻害
WO2020086857A1 (en) * 2018-10-24 2020-04-30 Vanderbilt University Wdr5 inhibitors and modulators
CN111320582A (zh) * 2018-12-17 2020-06-23 江苏恩华药业股份有限公司 一种类酰胺类衍生物及其中间体的制备方法
KR20200101219A (ko) * 2019-02-19 2020-08-27 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
BR112023002077A2 (pt) * 2020-08-13 2023-02-28 Hanmi Pharmaceutical Co Ltd Composto e seu uso, composição e formulação farmacêutica
KR102386403B1 (ko) * 2020-08-13 2022-04-15 한미약품 주식회사 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도
CN116457348A (zh) * 2021-02-26 2023-07-18 南京药石科技股份有限公司 新型ezh2抑制剂及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846412A (en) 1971-03-18 1974-11-05 Lepetit Spa Dihydro-2-amino-isoquinolines and their derivatives
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US20070093515A1 (en) 2005-08-16 2007-04-26 Arrington Mark P Phosphodiesterase 10 inhibitors
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
US20110251216A1 (en) 2010-02-19 2011-10-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
EP2566327B1 (en) 2010-05-07 2017-03-29 Glaxosmithkline LLC Indoles
US8846935B2 (en) 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
US8637509B2 (en) 2010-05-07 2014-01-28 Glaxosmithkline Llc Azaindazoles
US8895245B2 (en) 2010-09-10 2014-11-25 Epizyme, Inc. Inhibitors of human EZH2 and methods of use thereof
WO2012035078A1 (en) 2010-09-16 2012-03-22 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2012118812A2 (en) * 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TWI598336B (zh) * 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
KR20140082742A (ko) 2011-09-30 2014-07-02 글락소스미스클라인 엘엘씨 암을 치료하는 방법
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
CA2884848C (en) 2012-09-28 2017-08-22 Pfizer Inc. Benzamide and heterobenzamide compounds
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
MY191741A (en) 2012-12-21 2022-07-13 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
GEP201706757B (en) 2012-12-21 2017-10-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
AU2013363768B2 (en) 2012-12-21 2016-02-04 F. Hoffmann-La Roche Ag Peptides as oxytocin agonists
PL2935222T3 (pl) 2012-12-21 2019-02-28 Epizyme Inc Inhibitory PRMT5 i ich zastosowania
FR3000059A1 (fr) 2012-12-21 2014-06-27 Saint Gobain Placo Composition pour plaques de platre et produits obtenus
NZ711896A (en) 2012-12-21 2018-04-27 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
FR3000065A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
LT2934568T (lt) 2012-12-21 2018-02-12 Sanofi Dvigubi glp1/gip arba trigubi glp/gip/gliukagono agonistai
MY185765A (en) 2014-06-17 2021-06-06 Pfizer Substituted dihydroisoquinolinone compounds

Also Published As

Publication number Publication date
ES2658974T3 (es) 2018-03-13
AP2015008574A0 (en) 2015-07-31
RS60582B9 (sr) 2021-09-30
CY1123237T1 (el) 2021-10-29
UY35225A (es) 2014-07-31
DK3339303T3 (da) 2020-08-10
KR20150100823A (ko) 2015-09-02
MA38175B1 (fr) 2018-11-30
HK1208866A1 (en) 2016-03-18
EP3339303B9 (en) 2021-07-21
EA201590879A1 (ru) 2015-12-30
CR20150279A (es) 2015-09-03
GEP201706718B (en) 2017-08-10
DOP2015000157A (es) 2015-11-30
US20140179667A1 (en) 2014-06-26
GT201500190A (es) 2016-01-21
MX2015008058A (es) 2015-10-30
CN104870435B (zh) 2016-12-07
IL239520B (en) 2018-05-31
SI3339303T1 (sl) 2020-09-30
ZA201504437B (en) 2016-07-27
EP3339303B1 (en) 2020-06-24
UY38712A (es) 2020-06-30
TW201446753A (zh) 2014-12-16
PT2935238T (pt) 2018-02-09
SG11201504076XA (en) 2015-06-29
ECSP15031579A (es) 2017-08-31
EP2935238A1 (en) 2015-10-28
PE20151090A1 (es) 2015-08-07
WO2014097041A1 (en) 2014-06-26
CA2893339A1 (en) 2014-06-26
PL3339303T3 (pl) 2021-01-25
AR094174A1 (es) 2015-07-15
AU2013365908A1 (en) 2015-06-11
RS60582B1 (sr) 2020-08-31
AU2013365908C1 (en) 2018-01-25
DK2935238T3 (en) 2018-01-22
EP3339303A1 (en) 2018-06-27
HUE038238T2 (hu) 2018-10-29
US10246433B2 (en) 2019-04-02
CN104870435A (zh) 2015-08-26
AU2013365908B2 (en) 2017-07-20
ME03793B (me) 2021-04-20
MY176307A (en) 2020-07-28
US9040515B2 (en) 2015-05-26
PH12015501367B1 (en) 2015-09-02
CA2893339C (en) 2017-06-13
EP2935238B1 (en) 2017-12-27
JP5909308B2 (ja) 2016-04-26
US20150175572A1 (en) 2015-06-25
PT3339303T (pt) 2020-07-30
JP2016507497A (ja) 2016-03-10
NZ708801A (en) 2018-08-31
PL2935238T3 (pl) 2018-05-30
MY192259A (en) 2022-08-12
MD20150052A2 (ro) 2015-12-31
BR112015014678A2 (pt) 2017-07-11
HRP20201194T2 (hr) 2021-09-17
HRP20180060T1 (hr) 2018-02-23
UA111305C2 (uk) 2016-04-11
MX2020002924A (es) 2020-07-22
CU20150062A7 (es) 2015-11-27
ES2808987T9 (es) 2021-11-29
RS56815B1 (sr) 2018-04-30
IL239520A0 (en) 2015-08-31
TWI546293B (zh) 2016-08-21
CU24414B1 (es) 2019-05-03
LT3339303T (lt) 2020-09-10
MD4664B1 (ro) 2019-12-31
CR20200273A (es) 2020-09-23
SI2935238T1 (en) 2018-04-30
KR101712441B1 (ko) 2017-03-07
HUE050009T2 (hu) 2020-11-30
NO2961649T3 (tr) 2018-02-17
ES2808987T3 (es) 2021-03-02
MA38175A1 (fr) 2018-08-31
TN2015000281A1 (fr) 2016-10-03
CL2015001733A1 (es) 2015-10-23
HRP20201194T1 (hr) 2020-11-13
ME02980B (me) 2018-10-20
LT2935238T (lt) 2018-02-26
US20170233368A1 (en) 2017-08-17
PH12015501367A1 (en) 2015-09-02
MD4664C9 (ro) 2020-07-31
CY1119883T1 (el) 2018-06-27
EA028317B1 (ru) 2017-11-30

Similar Documents

Publication Publication Date Title
TR201802791T4 (tr) Aril ve heteroaril füzyonlu laktamlar.
CY1121706T1 (el) Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης
PH12015500263A1 (en) New bicyclic derivatives
MY169043A (en) New dihydroquinoline-2-one derivatives
IN2014DN09346A (tr)
PH12015501363B1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
MY178867A (en) New bicyclic dihydroisoquinoline-1-one derivatives
EA033513B1 (ru) Способы получения хинолиновых соединений и фармацевтических композиций, содержащих такие соединения
PE20150352A1 (es) Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
MY169267A (en) New aryl-quinoline derivatives
BR112012029647A2 (pt) novos derivados de pirimidinas
MD20160053A2 (ro) Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
MD20160111A2 (ro) Derivaţi diheterociclici legaţi de cicloalchil
MX2015012600A (es) Compuestos de tetrahidroisoquinolina-2-il-(quinazolina-4-il) metanona como inhibidores del crecimiento de células cancerígenas.
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
MX2014008856A (es) Derivados de imidazolilcetona como inhibidores de aldosterona sintasa.